246710.KQ
T&R Biofab Co., Ltd.
KOE · Healthcare · Medical - Specialties · KR
KRW 2,270.00
+1.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 32.7B | 27.0B | 4.9B | 5.2B | 5.8B |
| Cost of Revenue | 25.0B | 21.8B | 2.7B | 4.1B | 4.2B |
| Gross Profit | 7.8B | 5.2B | 2.1B | 1.1B | 1.5B |
| Operating Expenses | |||||
| R&D Expense | 3.3B | 8.0B | 5.5B | 4.4B | 3.9B |
| SG&A Expense | 4.2B | 4.4B | 2.9B | 2.3B | 2.3B |
| General & Admin Expense | 1.1B | 1.0B | 1.2B | 1.0B | 863.8M |
| Selling & Marketing Expense | 3.2B | 3.4B | 1.7B | 1.2B | 1.5B |
| Other Expenses | 9.8B | 4.8B | 7.0B | 7.2B | (603.1M) |
| Total Operating Expenses | 15.8B | 17.2B | 15.4B | 13.8B | 14.3B |
| Cost and Expenses | 38.4B | 39.0B | 18.2B | 17.9B | 18.5B |
| Operating Income (EBIT) | (5.6B) | (12.1B) | (13.3B) | (12.7B) | (12.9B) |
| Non-Operating | |||||
| Interest Income | 153.3M | 281.2M | 1.2B | 1.7B | 1.2B |
| Interest Expense | 8.0B | 6.1B | 2.2M | 3.2M | 1.9M |
| Net Interest Income | (7.8B) | (5.8B) | 1.2B | 1.7B | 577.0M |
| Other Non-Op Income/Expense | (25.1B) | (22.9B) | 5.6B | (695.2M) | 775.4M |
| Non-Operating Income (excl Interest) | 16.0B | 20.3B | (5.6B) | 691.9M | (777.3M) |
| EBT (Pre-Tax Income) | (30.7B) | (34.8B) | (7.7B) | (13.4B) | (10.3B) |
| Income Tax Expense | — | — | — | — | (12.5M) |
| Bottom Line | |||||
| Net Income | (30.7B) | (34.8B) | (7.7B) | (13.4B) | (10.3B) |
| Earnings from Cont. Ops | (30.7B) | (34.8B) | (7.7B) | (13.4B) | (10.3B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (30.6B) | (34.8B) | (7.7B) | (13.4B) | (10.3B) |
| Per Share | |||||
| Basic EPS | (₩801) | (₩760) | (₩356) | (₩633) | (₩496) |
| Diluted EPS | (₩801) | (₩760) | (₩356) | (₩633) | (₩496) |
| Revenue Per Share | ₩687 | ₩588 | ₩226 | ₩245 | ₩276 |
| Shares | |||||
| Basic Shares Outstanding | 47.7M | 45.9M | 21.6M | 21.2M | 20.8M |
| Diluted Shares Outstanding | 47.7M | 45.9M | 21.6M | 21.2M | 20.8M |
| Profitability Metrics | |||||
| EBITDA | (2.2B) | (7.1B) | (5.3B) | (11.3B) | (11.0B) |
| D&A | 4.9B | 4.9B | 2.4B | 2.2B | 1.9B |
| EBIT | (7.1B) | (12.1B) | (7.7B) | (13.4B) | (10.3B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026